ATE354574T1 - Neue purine derivate - Google Patents

Neue purine derivate

Info

Publication number
ATE354574T1
ATE354574T1 AT03748238T AT03748238T ATE354574T1 AT E354574 T1 ATE354574 T1 AT E354574T1 AT 03748238 T AT03748238 T AT 03748238T AT 03748238 T AT03748238 T AT 03748238T AT E354574 T1 ATE354574 T1 AT E354574T1
Authority
AT
Austria
Prior art keywords
compounds
disorders
unbranched
branched
independently
Prior art date
Application number
AT03748238T
Other languages
English (en)
Inventor
Peter Fischer
Michael Jarman
Edward Mcdonald
Bernard Nutley
Florence Raynaud
Stuart Wilson
Paul Workman
Original Assignee
Cyclacel Ltd
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE354574(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclacel Ltd, Cancer Rec Tech Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE354574T1 publication Critical patent/ATE354574T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
AT03748238T 2002-08-15 2003-08-13 Neue purine derivate ATE354574T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0219054.4A GB0219054D0 (en) 2002-08-15 2002-08-15 New purine derivatives

Publications (1)

Publication Number Publication Date
ATE354574T1 true ATE354574T1 (de) 2007-03-15

Family

ID=9942408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748238T ATE354574T1 (de) 2002-08-15 2003-08-13 Neue purine derivate

Country Status (17)

Country Link
US (2) US7582642B2 (de)
EP (1) EP1529047B8 (de)
JP (1) JP4723858B2 (de)
CN (1) CN1329393C (de)
AT (1) ATE354574T1 (de)
AU (1) AU2003267547B2 (de)
BR (1) BRPI0313477B8 (de)
CA (1) CA2492659C (de)
DE (1) DE60311995T2 (de)
DK (1) DK1529047T3 (de)
ES (1) ES2280773T3 (de)
GB (2) GB0219054D0 (de)
IL (1) IL166784A (de)
MX (1) MXPA05001843A (de)
NZ (1) NZ538135A (de)
PT (1) PT1529047E (de)
WO (1) WO2004016612A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
WO2007054725A2 (en) * 2005-11-11 2007-05-18 Cyclacel Limited Combination of a cdk-inhibitor and a hdac-inhibitor
DK1984353T3 (en) 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
MX2009010517A (es) 2007-04-05 2009-10-19 Amgen Inc Moduladores de cinasa aurora y metodos de uso.
DK2209786T3 (da) 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
JP2011515401A (ja) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
JP5363800B2 (ja) * 2008-12-25 2013-12-11 ライオン株式会社 育毛剤組成物
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
CN102428085B (zh) 2009-04-03 2015-07-15 维拉斯通股份有限公司 作为激酶抑制剂的嘧啶取代的嘌呤化合物
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
EP2907514B1 (de) 2014-02-17 2019-10-23 Manros Therapeutics Purinderivatverbindungen zur medizinischen Verwendung
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
AU2018213119B2 (en) 2017-01-26 2021-10-28 Cyclacel Limited Process for preparing purine derivatives
EP3388432A1 (de) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purinderivate zur verwendung als medikament und zur verwendung bei der behandlung neurodegenerativer oder neuroinflammatorischer erkrankungen
GB202000901D0 (en) * 2020-01-22 2020-03-04 Cyclacel Ltd Process
EP3901154A1 (de) * 2020-04-23 2021-10-27 Commissariat à l'énergie atomique et aux énergies alternatives Purinderivate als arzneimittel zur behandlung von neonataler hypoxie-ischämie-hirnverletzung und verwandten erkrankungen
CN116813621A (zh) * 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT874846E (pt) 1995-11-01 2003-08-29 Novartis Ag Derivados de purina e processos para a sua preparacao
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
WO1999034018A1 (en) 1997-12-24 1999-07-08 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
UA62996C2 (en) 1998-02-26 2004-01-15 Aventic Pharmaceuticals Inc 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines
DE60023268T2 (de) * 1999-02-01 2006-06-01 CV Therapeutics, Inc., Palo Alto INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives

Also Published As

Publication number Publication date
US20090325983A1 (en) 2009-12-31
DE60311995T2 (de) 2007-10-31
CA2492659A1 (en) 2004-02-26
CN1675211A (zh) 2005-09-28
EP1529047B1 (de) 2007-02-21
US20050256142A1 (en) 2005-11-17
AU2003267547A1 (en) 2004-03-03
EP1529047A2 (de) 2005-05-11
MXPA05001843A (es) 2005-04-19
NZ538135A (en) 2007-02-23
GB2392155B (en) 2005-03-30
GB0319256D0 (en) 2003-09-17
IL166784A (en) 2012-03-29
IL166784A0 (en) 2006-01-15
CA2492659C (en) 2012-07-17
BRPI0313477B8 (pt) 2021-05-25
DE60311995D1 (de) 2007-04-05
US7582642B2 (en) 2009-09-01
JP4723858B2 (ja) 2011-07-13
EP1529047B8 (de) 2010-05-19
CN1329393C (zh) 2007-08-01
PT1529047E (pt) 2007-03-30
WO2004016612A2 (en) 2004-02-26
JP2006506341A (ja) 2006-02-23
BR0313477A (pt) 2005-06-21
US8846696B2 (en) 2014-09-30
WO2004016612A3 (en) 2004-07-01
GB2392155A (en) 2004-02-25
GB0219054D0 (en) 2002-09-25
ES2280773T3 (es) 2007-09-16
AU2003267547B2 (en) 2009-06-18
DK1529047T3 (da) 2007-03-19
BRPI0313477B1 (pt) 2019-01-22

Similar Documents

Publication Publication Date Title
DE60311995D1 (de) Neue purine derivate
GB2392156B (en) New purine derivatives
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
DE602004017479D1 (de) Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
MX2009003410A (es) Fosfoindoles enantiomericamente puros como inhibidores de vih.
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
DE602005023015D1 (de) Indolderivate als viruzide
EP1117297A4 (de) Synthetische analoge des ecteinascidin-743
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
CY1108632T1 (el) Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
GB0510584D0 (en) Organic compounds
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
ATE361749T1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
AR039319A1 (es) Imidazolinilmetil aralquilsulfonamidas
ATE452876T1 (de) Aminoalkoholderivate
AR047967A1 (es) Derivados de pirimidina utiles para tratar enfermedades de reflujo gastro-esofagico.
BG105126A (en) Tetrahydronaphthyridinyl-carboxamides have anti-convulsant activity
WO2004094396A3 (en) Dihydrothiazine prodrugs of thiazolium agents
SE0100344D0 (sv) New Use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1529047

Country of ref document: EP